{"preliminary_commentary":{"by_channel":{"x_thread":10},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT01023308\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":{"generated_at":"2026-11-22T14:52:32.979Z","note":"Automated from the 9 newest of 10 indexed sources (Oct 2016 – Apr 2025). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.","passages_read":9,"text":"- Whether the results apply to lenalidomide-refractory patients, given how few were enrolled\n- How panobinostat-bortezomib-dexamethasone compares with daratumumab-, carfilzomib- or pomalidomide-based regimens across separate trial populations\n- Whether panobinostat-bortezomib-dexamethasone keeps a place in relapse sequencing as newer regimens arrive","kind":"questions"},"drugs_tested":[["panobinostat"]],"indication":"relapsed or relapsed and refractory multiple myeloma","name":"PANORAMA-1","nct_id":"NCT01023308","offer":{"currency":"USD","how":"Buy the first edition with create_order on https://mcp.erudio.com/mcp (product \"first_edition\", report \"NCT01023308\", the buyer's work email and organization), or POST https://www.erudio.com/api/orders with the same fields. It returns a Stripe checkout_url for your person to pay by card; a first edition has no agent-wallet payment. The person can also order on https://www.erudio.com/trials/panorama-1-nct01023308. We build the first edition within 24 hours of payment and email it to you once it passes our checks and review. If your report can't be delivered, we'll contact you and refund it in full.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"product":"first_edition","size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"PANORAMA-1","arms":[{"description":null,"label":"Panobinostat + Bortezomib + Dexamethasone","type":"EXPERIMENTAL"},{"description":null,"label":"Placebo + Bortezomib + Dexamethasone","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2015-07-30","type":"ACTUAL"},"conditions":["Multiple Myeloma"],"enrollment":{"count":767,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Panobinostat","otherNames":["LBH589"],"type":"DRUG"},{"name":"Bortezomib","otherNames":["(Velcade®)"],"type":"DRUG"},{"name":"Dexamethasone","otherNames":[],"type":"DRUG"},{"name":"Placebo","otherNames":[],"type":"DRUG"}],"last_update":"2020-03-17","lead_sponsor":"Novartis Pharmaceuticals","official_title":"A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2015-07-30","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-free Survival Events in Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone.","timeFrame":"45 months"},{"measure":"Progression Free Survival in Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone.","timeFrame":"45 months"}],"references":[{"citation":"San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Gunther A, Nakorn TN, Siritanaratkul N, Schlossman RL, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Sopala M, Bengoudifa BR, Binlich F, Richardson PG. Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial. Lancet Haematol. 2016 Nov;3(11):e506-e515. doi: 10.1016/S2352-3026(16)30147-8. Epub 2016 Oct 14.","pmid":"27751707","type":"DERIVED"},{"citation":"San-Miguel JF, Einsele H, Moreau P. The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective. Adv Ther. 2016 Nov;33(11):1896-1920. doi: 10.1007/s12325-016-0413-7. Epub 2016 Sep 27.","pmid":"27677481","type":"DERIVED"},{"citation":"Richardson PG, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Guenther A, Nakorn TN, Siritanaratkul N, Schlossman RL, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Sopala M, Bengoudifa BR, Corrado C, Binlich F, San-Miguel JF. Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. Blood. 2016 Feb 11;127(6):713-21. doi: 10.1182/blood-2015-09-665018. Epub 2015 Dec 2.","pmid":"26631116","type":"DERIVED"},{"citation":"San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Gunther A, Nakorn TN, Siritanaratkul N, Corradini P, Chuncharunee S, Lee JJ, Schlossman RL, Shelekhova T, Yong K, Tan D, Numbenjapon T, Cavenagh JD, Hou J, LeBlanc R, Nahi H, Qiu L, Salwender H, Pulini S, Moreau P, Warzocha K, White D, Blade J, Chen W, de la Rubia J, Gimsing P, Lonial S, Kaufman JL, Ocio EM, Veskovski L, Sohn SK, Wang MC, Lee JH, Einsele H, Sopala M, Corrado C, Bengoudifa BR, Binlich F, Richardson PG. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014 Oct;15(11):1195-206. doi: 10.1016/S1470-2045(14)70440-1. Epub 2014 Sep 18.","pmid":"25242045","type":"DERIVED"}],"start_date":{"date":"2009-12-21","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma","url":"https://clinicaltrials.gov/study/NCT01023308"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/panorama-1-nct01023308"}